Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer

被引:205
作者
Chollet, P
Amat, S
Cure, H
de Latour, M
Le Bouedec, G
Mouret-Reynier, MA
Ferriere, JP
Achard, JL
Dauplat, J
Penault-Llorca, F
机构
[1] Ctr Jean Perrin, Bur Rech Clin, F-63011 Clermont Ferrand 1, France
[2] INSERM, U484, F-63005 Clermont Ferrand, France
关键词
pathological response; prognostic factor; breast cancer; neoadjuvant chemotherapy;
D O I
10.1038/sj/bjc/6600210
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Only a few papers have been published concerning the incidence and outcome of patients with a pathological complete response after cytotoxic treatment in breast cancer. The purpose of this retrospective study was to assess the outcome of patients found to have a pathological complete response in both the breast and axillary lymph nodes after neoadjuvant chemotherapy for operable breast cancer. Our goal was also to determine whether the residual pathological size of the tumour in breast could be correlated with pathological node status. Between 1982 and 2000, 45 1 consecutive patients were registered into five prospective phase 11 trials. After six cycles, 396 patients underwent surgery with axillary dissection for 277 patients (69.9%). Pathological response was evaluated according to the Chevallier's classification. At a median follow-up of 8 years, survival was analysed as a function of pathological response. A pathological complete response rate was obtained in 60 patients (15.2%) after induction chemotherapy. Breast tumour persistence was significantly related to positive axillary nodes (P=5.10(-6)). At 15 years, overall survival and disease-free survival rates were significantly higher in the group who had a pathological complete response than in the group who had less than a pathological complete response (P=0.047 and P=0.024, respectively). In the absence of pathological complete response and furthermore when there is a notable remaining pathological disease, axillary dissection is still important to determine a major prognostic factor and subsequently, a second non cross resistant adjuvant regimen or high dose chemotherapy could lead to a survival benefit. (C) 2002 Cancer Research UK.
引用
收藏
页码:1041 / 1046
页数:6
相关论文
共 33 条
  • [1] NEOADJUVANT CHEMOTHERAPY IN 126 OPERABLE BREAST CANCERS
    BELEMBAOGO, E
    FEILLEL, V
    CHOLLET, P
    CURE, H
    VERRELLE, P
    KWIATKOWSKI, F
    ACHARD, JL
    LEBOUEDEC, G
    CHASSAGNE, J
    BIGNON, YJ
    DELATOUR, M
    LAFAYE, C
    DAUPLAT, J
    [J]. EUROPEAN JOURNAL OF CANCER, 1992, 28A (4-5) : 896 - 900
  • [2] Primary chemotherapy in operable breast cancer: Eight-year experience at the Milan Cancer Institute
    Bonadonna, G
    Valagussa, P
    Brambilla, C
    Ferrari, L
    Moliterni, A
    Terenziani, M
    Zambetti, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (01) : 93 - 100
  • [3] Long-term prognostic and predictive factors in 107 stage II/III breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy
    Brain, E
    Garrino, C
    Misset, JL
    Carbonero, IG
    Itzhaki, M
    Cvitkovic, E
    Goldschmidt, E
    Burki, F
    Regensberg, C
    Pappo, E
    Hagipantelli, R
    Musset, M
    [J]. BRITISH JOURNAL OF CANCER, 1997, 75 (09) : 1360 - 1367
  • [4] INFLAMMATORY BREAST-CANCER - PILOT-STUDY OF INTENSIVE INDUCTION CHEMOTHERAPY (FEC-HD) RESULTS IN A HIGH HISTOLOGIC RESPONSE RATE
    CHEVALLIER, B
    ROCHE, H
    OLIVIER, JP
    CHOLLET, P
    HURTELOUP, P
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1993, 16 (03): : 223 - 228
  • [5] Clinical and pathological response to primary chemotherapy in operable breast cancer
    Chollet, P
    Charrier, S
    Brain, E
    Cure, H
    vanPraagh, I
    Feillel, V
    deLatour, M
    Dauplat, J
    Misset, JL
    Ferriere, JP
    [J]. EUROPEAN JOURNAL OF CANCER, 1997, 33 (06) : 862 - 866
  • [6] CHOLLET P, 2000, BREAST CANC RES TREA, V64, P67
  • [7] COX DR, 1972, J R STAT SOC B, V34, P187
  • [8] The efficacy of neoadjuvant chemotherapy compared to postoperative therapy in the treatment of locally advanced breast cancer
    Cunningham, JD
    Weiss, SE
    Ahmed, S
    Bratton, JM
    Bleiweiss, IJ
    Tartter, PI
    Brower, ST
    [J]. CANCER INVESTIGATION, 1998, 16 (02) : 80 - 86
  • [9] COMBINED CHEMOTHERAPY-RADIOTHERAPY APPROACH IN LOCALLY ADVANCED (T3B-T4) BREAST-CANCER
    DELENA, M
    ZUCALI, R
    VIGANOTTI, G
    VALAGUSSA, P
    BONADONNA, G
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1978, 1 (01) : 53 - 59
  • [10] FELDMAN LD, 1986, CANCER RES, V46, P2578